Cargando…

Outcome of Elective Checkpoint Inhibitor Discontinuation in Patients with Metastatic Melanoma Who Achieved a Complete Remission: Real-World Data

Checkpoint inhibitor therapy for metastatic melanoma has dramatically improved outcomes. Currently, 20 to 40% of treated patients achieve lengthy remissions. It is not clear whether patients in remission require ongoing therapy or if treatment can be safely discontinued. A retrospective chart review...

Descripción completa

Detalles Bibliográficos
Autores principales:	Perez, Leanne, Samlowski, Wolfram, Lopez-Flores, Ruby
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9138966/ https://www.ncbi.nlm.nih.gov/pubmed/35625881 http://dx.doi.org/10.3390/biomedicines10051144

Ejemplares similares

Retreatment of Patients With Metastatic Cutaneous Melanoma Who Relapse After Elective Checkpoint Inhibitor Discontinuation After a Complete Remission
por: Sadrolashrafi, Kaviyon, et al.
Publicado: (2023)

Cautious addition of targeted therapy to PD-1 inhibitors after initial progression of BRAF mutant metastatic melanoma on checkpoint inhibitor therapy
por: Samlowski, Wolfram, et al.
Publicado: (2021)

Real-world analyses of therapy discontinuation of checkpoint inhibitors in metastatic melanoma patients
por: Machado, Marina Amaral de Ávila, et al.
Publicado: (2020)

Real-world experience with elective discontinuation of PD-1 inhibitors at 1 year in patients with metastatic melanoma
por: Pokorny, Rebecca, et al.
Publicado: (2021)

Lack of Influence of Non-Overlapping Mutations in BRAF, NRAS, or NF1 on 12-Month Best Objective Response and Long-Term Survival after Checkpoint Inhibitor-Based Treatment for Metastatic Melanoma
por: Panning, Alyssa, et al.
Publicado: (2023)

Discontinuation of BRAF/MEK-Directed Targeted Therapy after Complete Remission of Metastatic Melanoma—A Retrospective Multicenter ADOReg Study
por: Stege, Henner, et al.
Publicado: (2021)

Management of Melanoma Brain Metastases in the Era of Targeted Therapy
por: Shapiro, Daniela Gonsalves, et al.
Publicado: (2011)

Metabolic imaging with FDG-PET and time to progression in patients discontinuing immune-checkpoint inhibition for metastatic melanoma
por: Ferdinandus, Justin, et al.
Publicado: (2022)

Checkpoint Inhibition Causing Complete Remission of Metastatic Combined Hepatocellular-Cholangiocarcinoma after Hepatic Resection
por: Rizell, Magnus, et al.
Publicado: (2020)

Complete remission in metastatic primary malignant melanoma of the esophagus with nivolumab: a case report
por: Okamoto, Takeshi, et al.
Publicado: (2021)

Real-World Impact of Immune Checkpoint Inhibitors in Metastatic Uveal Melanoma
por: Bol, Kalijn Fredrike, et al.
Publicado: (2019)

Treatment of recurrent mucosal melanoma of the oral cavity with topical imiquimod and pembrolizumab achieves complete histopathologic remission
por: Satish, Tejus, et al.
Publicado: (2021)

Complete remission in metastatic hepatocellular carcinoma
por: Ben Kridis, Wala, et al.
Publicado: (2023)

Real‐World nivolumab dosing patterns and safety outcomes in patients receiving adjuvant therapy for melanoma
por: Samlowski, Wolfram, et al.
Publicado: (2022)

Prediction of disease flare by biomarkers after discontinuing biologics in patients with rheumatoid arthritis achieving stringent remission
por: Kameda, Hideto, et al.
Publicado: (2021)

Long-term outcomes of patients with advanced hepatocellular carcinoma who achieved complete remission after sorafenib therapy
por: Park, Jung Gil
Publicado: (2015)

Long‐term outcomes in patients with advanced and/or metastatic non–small cell lung cancer who completed 2 years of immune checkpoint inhibitors or achieved a durable response after discontinuation without disease progression: Multicenter, real‐world data (KCSG LU20‐11)
por: Kim, Hongsik, et al.
Publicado: (2021)

Discontinuation of adalimumab after achieving remission in patients with established rheumatoid arthritis: 1-year outcome of the HONOR study
por: Tanaka, Yoshiya, et al.
Publicado: (2015)

Case analysis of complete remission of advanced hepatocellular carcinoma achieved with sorafenib
por: Liu, Daizhong, et al.
Publicado: (2015)

Time to achieve remission determines time to be in remission
por: Schipper, Lydia G, et al.
Publicado: (2010)

Complete Remission in Metastatic Pheochromocytoma Treated with Extensive Surgery
por: Arnas-Leon, Claudia, et al.
Publicado: (2016)

Correction: Discontinuation of adalimumab after achieving remission in patients with established rheumatoid arthritis: 1-year outcome of the HONOR study
Publicado: (2016)

Identification of patients who will not achieve seizure remission within 5 years on AEDs
por: Hughes, David M., et al.
Publicado: (2018)

Surveillance Strategy for Patients With BCLC Stage B Hepatocellular Carcinoma After Achieving Complete Remission: Data From the Real World
por: Wu, Ying, et al.
Publicado: (2020)

Multidisciplinary treatment in pulmonary metastasis of a mesorectal angiosarcoma achieving complete remission
por: Zhou, Ding, et al.
Publicado: (2020)

Complete remission of metastatic renal cell carcinoma to the bone with sunitinib
por: Yoshimura, Akihiro, et al.
Publicado: (2020)

The benefit of consolidation radiotherapy to initial disease bulk in patients with advanced Hodgkin’s disease who achieved complete remission after standard chemotherapy
por: Bayoumi, Yasser, et al.
Publicado: (2015)

Comparison of Efficacy in Patients with Metastatic Melanoma Treated with Ipilimumab and Nivolumab Who Did or Did Not Discontinue Treatment Due to Immune-Related Adverse Events: A Real-World Data Study
por: Fink, Morten, et al.
Publicado: (2021)

Discontinuation of Azathioprine could be considered in pediatric patients with Crohn’s disease who have sustained clinical and deep remission
por: Jeong, Tae Jong, et al.
Publicado: (2022)

Delayed presentation of a metastatic choroidal melanoma to the liver: The latency of an elective metastatic localization
por: Pesce, Antonio, et al.
Publicado: (2015)

Immunotherapy Discontinuation in Metastatic Melanoma: Lessons from Real-Life Clinical Experience
por: Asher, Nethanel, et al.
Publicado: (2021)

Complete Remission of Mouse Melanoma after Temporally Fractionated Microbeam Radiotherapy
por: Fernandez-Palomo, Cristian, et al.
Publicado: (2020)

Discontinuation of anti‑programmed cell death protein 1 immune checkpoint inhibition after complete remission in head and neck squamous cell carcinoma: A case report and literature review
por: Stöth, Manuel, et al.
Publicado: (2023)

Early discontinuation of PD-1 blockade upon achieving a complete or partial response in patients with advanced melanoma: the multicentre prospective Safe Stop trial
por: Mulder, E. E. A. P., et al.
Publicado: (2021)

Phase II clinical trial evaluating docetaxel, vinorelbine and GM-CSF in stage IV melanoma
por: Eroglu, Zeynep, et al.
Publicado: (2011)

[(18)F]Fluorodeoxyglucose Positron Emission Tomography Reveals a Complete Remission of Refractory Metastatic Melanoma after Therapy with Ipilimumab
por: Yordanova, Anna, et al.
Publicado: (2017)

Enhancement of Antiviral CD8(+) T-Cell Responses and Complete Remission of Metastatic Melanoma in an HIV-1-Infected Subject Treated with Pembrolizumab
por: Blanch-Lombarte, Oscar, et al.
Publicado: (2019)

Complete remission achieved by oophorectomy for recurrent endometrial stromal sarcoma after laparoscopic morcellation
por: Inoue, Kayo, et al.
Publicado: (2014)

Recurrence of Chronic Myeloid Leukemia during Pregnancy Subsequently Achieving Complete Medical Remission
por: Mikhael, Sasha, et al.
Publicado: (2017)

The first achievement of complete remission in childhood leukemia by treatment with the folic acid antagonist aminopterin
por: Izraeli, Shai
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_d1ohrcmmq78rfki3i16c59p4hq